BioLineRx to Present at 15th International Celiac Disease Symposium
News Sep 20, 2013
BioLineRx has announced that its abstract entitled "BL-7010: Non-Absorbable Polymeric Sequestering Agent for Celiac Disease" was accepted for an oral presentation at the 15th International Celiac Disease Symposium, which will take place September 22-25, 2013 in Chicago.
Yotam Nisemblat, Senior Drug Development Manager at BioLineRx, will present BL-7010 for the treatment of celiac as part of a session entitled, "The Non-Responsive Celiac: What's New?"
"We are honored to present BL-7010 at the leading international celiac conference and are excited that the scientific and medical communities share our enthusiasm for this promising and unique product," stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx.
Dr. Savitsky continued, "Despite the unmet medical need and the huge size of the celiac market, there is currently no treatment for the disease apart from a lifelong gluten-free diet, which is extremely difficult to maintain."
"We look forward to commencing a Phase 1/2 study for BL-7010 by the end of this year. The CRO and treatment sites in Europe have already been selected, and we are in the midst of preparing the necessary regulatory submissions for the study," concluded Dr. Savitsky.
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE